AGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agenus Inc (AGEN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock has shown significant recent price declines (-8.75% in regular trading), weak financial performance in the latest quarter, and no strong trading signals. While the company has upcoming catalysts such as earnings and strategic updates, the current technical and financial data suggest waiting for more clarity before investing.
The stock is trading near its key support level (S1: 2.981), with MACD showing positive contraction but RSI at 28.587 indicating oversold conditions. Moving averages are converging, suggesting indecision in the market. Overall, the technical indicators do not provide a strong buy signal.
Upcoming Q4 2025 earnings report on March 13, 2026, which could provide clarity on financial performance.
Stakeholder briefing webcast in late March to discuss strategic plans and data milestones.
Positive clinical trial data for botensilimab and balstilimab in late-line cancers.
Significant recent price decline (-8.75% in regular trading).
Weak financial performance in Q3 2025, with net income and EPS showing sharp declines.
No strong hedge fund or insider trading activity to indicate confidence in the stock.
In Q3 2025, revenue increased by 20.40% YoY to $30.24M, but net income dropped by -196.12% YoY to -$63.86M. EPS also declined by -162.99% YoY to -$1.94, and gross margin slightly decreased to 97.88%. Overall, financial performance is weak despite revenue growth.
No recent analyst rating or price target changes are available for AGEN.
